Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AUTOIMMUNE DISEASES, CONTAINING DENDRITIC CELLS WITH OVEREXPRESSED DAB2 GENE
Document Type and Number:
WIPO Patent Application WO/2015/163702
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases and, more specifically, to a pharmaceutical composition for preventing or treating autoimmune diseases, containing semi-mature dendritic cells with overexpressed Dab2 gene. The composition according to the present invention contains, as an active ingredient, semi-mature dendritic cells with overexpressed Dab2 gene or increased Dab2 protein activity. The semi-mature dendritic cells with overexpressed Dab2 gene or increased Dab2 protein activity can suppress the proliferation of antigen-specific effector T cells, inhibit the expression of inflammatory cytokines, and increase the proportion of anti-inflammatory cytokine expression and regulatory T cells, and thus are expected to be favorably used as a pharmaceutical composition for preventing, alleviating, or treating autoimmune diseases including arthritis.
Inventors:
BAE YONG-SOO (KR)
BYEON SE EUN (KR)
SELIM AHMED (KR)
JEONG YIDEUL (KR)
BYEON SE EUN (KR)
SELIM AHMED (KR)
JEONG YIDEUL (KR)
Application Number:
PCT/KR2015/004043
Publication Date:
October 29, 2015
Filing Date:
April 23, 2015
Export Citation:
Assignee:
UNIV SUNGKYUNKWAN RES & BUS (KR)
International Classes:
A61K35/12; A61K39/395; A61P19/02; A61P29/00
Foreign References:
| KR20080095343A | 2008-10-29 | |||
| KR20080078204A | 2008-08-27 |
Other References:
MIAH, MOHAMMAD ALAM ET AL.: "Egr2 induced during DC development acts as an intrinsic negative regulator of DC immunogenicity", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 43, no. 9, 2013, pages 2484 - 2496, XP055233173, ISSN: 0014-2980
JAIN, NITYA ET AL.: "Cutting edge: Dab2 is a FOXP3 target gene required for regulatory T cell function", THE JOURNAL OF IMMUNOLOGY, vol. 183, no. 7, 2009, pages 4192 - 4196, XP055185293, ISSN: 0022-1767
JOKUBAITIS, VILIJA G. ET AL.: "Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis", ACTA NEUROPATHOLOGICA COMMUNICATIONS, vol. 1, no. 32, 2013, pages 1 - 14, XP021157685, ISSN: 2051-5960
AHMEDA, MD . SELIM ET AL.: "Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy", ONCOLMMUNOLOGY, vol. 4, no. 1, January 2015 (2015-01-01), pages e984550 - 1-e984550-15, XP009183877, ISSN: 2162-4011
JAIN, NITYA ET AL.: "Cutting edge: Dab2 is a FOXP3 target gene required for regulatory T cell function", THE JOURNAL OF IMMUNOLOGY, vol. 183, no. 7, 2009, pages 4192 - 4196, XP055185293, ISSN: 0022-1767
JOKUBAITIS, VILIJA G. ET AL.: "Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis", ACTA NEUROPATHOLOGICA COMMUNICATIONS, vol. 1, no. 32, 2013, pages 1 - 14, XP021157685, ISSN: 2051-5960
AHMEDA, MD . SELIM ET AL.: "Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy", ONCOLMMUNOLOGY, vol. 4, no. 1, January 2015 (2015-01-01), pages e984550 - 1-e984550-15, XP009183877, ISSN: 2162-4011
Attorney, Agent or Firm:
LEE, MYOUNG-JIN (KR)
이명진 (KR)
이명진 (KR)
Download PDF: